Arcadia Biosciences Inc reports results for the quarter ended in March - Earnings Summary
10/05/2024 24:43
* Arcadia Biosciences Inc RKDA.OQ reported a quarterly
adjusted
loss of $1.78 per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-10.86. The mean expectation of two analysts for the
quarter was for a loss of $2.21 per share. Wall Street expected
results to range from $-2.52 to $-1.91 per share.
* Revenue fell 16.8% to $1.26 million from a year ago;
analysts
expected $1.19 million.
* Arcadia Biosciences Inc's reported EPS for the quarter was
a
loss of $1.78.
* The company reported a quarterly loss of $2.42 million.
* Arcadia Biosciences Inc shares had fallen by 10.4% this
quarter and lost 36.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the agricultural
chemicals peer group is also "buy"
Wall Street's median 12-month price target for Arcadia
Biosciences Inc is $11.00
This summary was machine generated from LSEG data May 9 at 11:43
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -2.21 -1.78 Beat
Dec. 31 2023 -2.58 -2.52 Beat
Sep. 30 2023 -3.19 -1.44 Beat
Jun. 30 2023 -4.80 -2.65 Beat